Trials / Completed
CompletedNCT02349425
A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010)
A Dose Escalation Study to Assess the Efficacy and Tolerance of AF-219 in Subjects With Refractory Chronic Cough
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A randomized, double-blind, placebo-controlled, crossover, dose escalation study to assess the efficacy and tolerability of gefapixant (AF-219; MK-7264) in participants with refractory chronic cough.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gefapixant | Gefapixant 7.5 and 50mg tablets administered orally |
| DRUG | Placebo (for gefapixant) | Placebo to gefapixant 7.5 and 50mg tablets administered orally |
Timeline
- Start date
- 2015-03-09
- Primary completion
- 2016-02-01
- Completion
- 2016-02-09
- First posted
- 2015-01-28
- Last updated
- 2020-10-22
- Results posted
- 2020-10-22
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02349425. Inclusion in this directory is not an endorsement.